Antithrombotic therapy in children

Progress in Pediatric Cardiology

Volumn 21, Issue 1, 2005, Pages 31-43

  Chalmers, Elizabeth A ^a   Bonduel, Mariana M ^b  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^b NONE   (Argentina)

Author keywords

Anticoagulant; Children; Thrombosis

Indexed keywords

ABCIXIMAB; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A INHIBITOR; CLOPIDOGREL; COUMARIN DERIVATIVE; DANAPAROID; DIPYRIDAMOLE; ENOXAPARIN; HEPARIN; HIRUDIN; HIRULOG; LEVIPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENPROCOUMON; PROTAMINE SULFATE; RECOMBINANT HIRUDIN; REVIPARIN; ROFECOXIB; THROMBIN INHIBITOR; THROMBOMODULIN; TICLOPIDINE; UNINDEXED DRUG; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLALOCK TAUSSIG ANASTOMOSIS; BLEEDING; CALCIFICATION; CHILD; CLINICAL TRIAL; COMORBIDITY; CONGENITAL HEART DISEASE; CORONARY STENT; DEVICE; FONTAN PROCEDURE; GASTROINTESTINAL HEMORRHAGE; HAIR LOSS; HEART CATHETERIZATION; HEART VALVE PROSTHESIS; HUMAN; MOYAMOYA DISEASE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEUTROPHILIA; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SKIN NECROSIS; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRACHEA DISEASE; TREATMENT INDICATION;

EID: 28844486290     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2005.09.005     Document Type: Article

References (127)

1. M. Andrew, M. David, and M. Adams Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE Blood 83 5 1994 1251 1257
2. C.H. van Ommen, H. Heijboer, H.R. Buller, R.A. Hirasing, H.S. Heijmans, and M. Peters Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands J Pediatr 139 5 2001 676 681
3. B.E.S. Gibson, E.A. Chalmers, P. Bolton-Maggs, D.J. Henderson, and R. Lynn Thromboembolism in childhood: a prospective two year BPSU study in the United Kingdom. February 2001-February 2003 Thromb Haemost 1 Suppl. 1 2003 OC422
4. M. Andrew, B. Paes, and R. Milner Development of the coagulation system in the full term infant Blood 70 1987 165 172
5. M. Andrew, B. Paes, and R. Milner Development of the coagulation system in the healthy premature infant Blood 72 1988 1651 1657
6. B. Schmidt, M. Buchanan, F. Ofosu, L. Brooker, J. Hirsh, and M. Andrew Antithrombotic properties of heparin in a neonatal piglet model of thrombin induced thrombosis Thromb Haemost 60 1988 289 292
7. E. Young, M.H. Prins, and M.N. Levine Heparin binding to plasma proteins, an important mechanism for heparin resistance Thromb Haemost 67 1992 639 643
8. J. Hirsh Heparin N Engl J Med 324 1991 1565 1574
9. A. Vieira, L. Berry, F. Ofosu, and M. Andrew Heparin sensitivity and resistance in the neonate: an explanation Thromb Res 63 1991 85 98
10. M. Andrew, F. Ofosu, B. Schmidt, L. Brooker, J. Hirsh, and M. Bichanan Heparin clearance and ex vivo recovery in newborn piglets and adult pigs Thromb Res 52 1988 517 527
11. M. Andrew, V. Marzinotto, and P. Massicotte Heparin therapy in pediatric patients: a prospective cohort study Pediatr Res 35 1994 78 83
12. B.H. Chong Heparin induced thrombocytopenia J Thromb Haemost 1 2003 1471 1478
13. L.K. Boshkov, T.E. Warkentin, and C.PM. Hayward Heparin induced thrombocytopenia and thrombosis: clinical and laboratory studies Br J Haematol 84 1993 322 328
14. T.E. Warkentin, J.I. Sheppard, and P. Horsewood Impact of the clinical population on the risk of heparin induced thrombocytopenia Blood 96 2000 1703 1708
15. I.A. Murdoch, R.M. Beattie, and D.M. Silver Heparin induced thrombocytopenia in children Acta Paediatr 82 1993 495 497
16. T. Severin, and A.H. Sutor Heparin induced thrombocytopenia in paediatrics Semin Thromb Hemost 27 2001 293 299
17. M. Schmugge, L. Risch, and A. Huber Heparin induced thrombocytopenia associated with thrombosis in paediatric intensive care patients Pediatrics 109 2002 e10
18. L.V. Avioli Heparin induced osteopenia: an appraisal Adv Exp Med Biol 52 1975 375 387
19. M.S. Murphy, P.R. John, and A.D. Mayer Heparin therapy and bone fractures Lancet 340 1992 1098
20. J.L. Weitz Low molecular weight heparins N Engl J Med 337 1997 688 698
21. E. Young, B. Cosmi, J. Weitz, and J. Hirsh Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (Enoxaparin) to plasma proteins Thromb Haemost 70 1993 625 630
22. J. Fareed, W.L. Leong, and D.A. Hoppensteadt Generic low-molecular-weight heparins: some practical considerations Semin Thromb Haemost 30 2004 703 713
23. P. Monagle, A. Chan, E. Chalmers, and A.D. Michelson Antithrombotic therapy in children: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 645S 687S
24. P. Massicotte, J. Julian, and M. Gent An open label randomised controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trail Thromb Res 109 2003 85 92
25. D. Dix, M. Andrew, and V. Marzinotto The use of low molecular weight heparin in pediatric patients: a prospective cohort study J Paediatr 136 2000 439 445
26. J. Ansell, J. Hirsh, L. Poller, H. Bussey, A. Jacobson, and E. Hylek The pharmacology and management of the vitamin K antagonists. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 204S 233S
27. M. Andrew, V. Marzinotto, and L.A. Brooker Oral anticoagulation therapy in pediatric patients: a prospective study Thromb Haemost 71 1994 265 269
28. W. Streif, M. Andrew, and V. Marzinotto Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients Blood 94 1999 3007 3014
29. M. Bonduel, G. Sciuccati, and M. Hepner Acenocoumarol therapy in pediatric patients J Thromb Haemost 1 2003 1740 1743
30. U. Carpentieri, Q.X. Nghiem, and L.C. Harris Clinical experience with an oral anticoagulant in children Arch Dis Child 51 1976 445 448
31. J.J. Doyle, G. Koren, M.Y. Cheng, and V.S. Blanchette Anticoagulation with sodium warfarin in children: effect of a loading regimen J Pediatr 113 1988 1095
32. D.I.K. Evans, M. Rowlands, and L. Poller Survey of oral anticoagulant treatment in children J Clin Pathol 45 1992 707 708
33. A. Woods, J. Vargas, G. Berri, G. Kreutzer, S. Meschengieser, and M.A. Lazzari Antitrhombotic therapy in children and adolescents Thromb Res [Suppl] 42 1986 289 301
34. C. Pattacini, C. Manotti, M. Pini, R. Quintavalla, and A.G. Dettori A comparative study on the quality of oral anticoagulant therapy (wrfarin versus acenocoumarol) Thromb Haemost 71 1994 188 191
35. G. Palareti, N. Leali, and S. Coccheri Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study [ISCOAT] Lancet 348 1996 423 428
36. A. Aiman, J.N. Rodriguez, and R. Muñiz Estudio comparativo de la estabilidad del tratamiento anticoagulante oral [warfarina versus acenocumarol] Sangre 41 1996 9 11
37. D. Barcellona, M.L. Vannini, L. Fenu, C. Balestrieri, and F. Marongiu Warfarin or acenocoumarol: which is better in the management of oral anticoagulants? Thromb Haemost 80 1998 899 902
38. P. Casais, A.S. Luceros, S. Meschengieser, E. Bermejo, and M.A. Lazzari INR variability in anticoagulation with acenocoumarol: is it useful for identifying patients at risk of bleeding and thrombosis? Haematologica 84 1999 753 754
39. F. Veiga, A. Escriba, and M.P. Maluenda Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial Thromb Haemost 84 2000 559 564
40. P. Piquet, J. Losay, and S. Doubine Acenocoumarol [Sintrom®] and fluindione [Previscan®] in pediatrics after cardiac surgery Arch Pediatr 9 2002 1137 1144
41. A.P.A. Gadisseur, F.J.M. van del Meer, H.J. Adriaansen, S.D. Fihn, and F.R. Rosendaal Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon Br J Haematol 117 2002 940 946
42. C. Vermeer gg-Carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase Biochem J 266 1990 625 636
43. G. Ferland The vitamin K-dependent proteins: an update Nutr Rev 56 1998 223 230
44. C.L. Crespi, and V.P. Miller The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase Pharmacogenetics 7 1997 203 210
45. C.L. Crespi, and V.P. Miller The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase Pharmacogenetics 7 1997 203 210
46. K. Takanashi, H. Tainaka, K. Kobayashi, T. Yasumori, M. Hosakawa, and K. Chiba CYP2C9 Ile359 and Leu 359 variants: enzyme kinetic study with seven substrates Pharmacogenetics 10 2000 95 104
47. M. Margaglione, D. Colaizzo, and G. D'Andrea Genetic modulation of oral anticoagulation with warfarin Thromb Haemost 84 2000 775 778
48. H.H.W. Thijssen, and B. Ritzen Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype Clin Pharmacol Ther 74 2003 61
49. K.O. Haustein Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocumon Semin Thromb Hemost 25 1999 5 11
50. M. Andrew, P.T. Monagle, and L. Brooker M. Andrew P.T. Monagle L. Brooker Developmental hemostasis: relevance to thromboembolic complications in pediatric patients 2000 Decker Inc BC Hamilton, London 5 46
51. P. Massicote, M. Leaker, and V. Marzinotto Enhanced thrombin regulation during warfarin therapy in children compared to adults Thromb Haemost 80 1998 570 574
52. T.A. Kuhn, W.R. Garnett, B.K. Wells, and H.T. Karnes Recovery of warfarin from an enteral nutrient formula Am J Hosp Pharm 46 1989 1395 1399
53. C. Biron, P. Licznar, S. Hansel, and J.F. Schved Oral anticoagulant drugs: do not cut tablets in quarters Thromb Haemost 82 1999 1201
54. V. Marzinotto, P. Monagle, A. Chan, P. Massicotte, M. Leaker, and M. Andrew Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinic and the home setting Pediatr Cardiol 21 2000 347 352
55. W.L. Nowatzke, M. Landt, C. Smith, T. Wilhite, C. Canter, and L. Luchtman-Jones Whole blood international normalization ratio measurements in children using near-patient monitors J Pediatr Hematol Oncol 25 2003 33 37
56. A.M. Cheung, J. Halton, and M. Dinyari Bone mineral density (BMD) in a cohort of children on long term warfarin therapy (> 1 year) (abstract) J Thromb Haemost 2001 1729 [Suppl]
57. T. Hooshang, and M. Capitanio Tracheobronchial calcification: an observation in three children after mitral valve replacement and warfarin sodium therapy Radiology 176 1990 728 730
58. L. Gatti, V. Carnelli, R. Rusconi, and M. Moia Heparin-induced thrombocytopenia and warfarin-induced skin necrosis in a child with severe protein C deficiency: successful treatment with dermatan sulfate and protein C concentrate J Thromb Haemost 2 2003 387 388
59. C. Bony, F. Zyka, I. Tiran-Rajaofera, T. Attali, S. De Napoli, and J.L. Alessandri Warfarin fetopathy Arch Pediatr 9 2002 705 708
60. J. Hirsh, M. O'Donnell, and J.I. Weitz New anticoagulants Blood 105 2005 453 463
61. A.F. Klenner, N. Lubenow, R. Raschke, and A. Greinacher Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature Thromb Haemost 91 2004 719 724
62. S. Haas The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes Semin Thromb Hemost 3 2003 139 146
63. C. Patrono, B. Coller, G.A. FitzGerald, J. Hirsh, and G. Roth Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 234S 264S
64. K.K. Wu Aspirin and other cyclooxygenase inhibitors: new therapeutic insights Semin Vasc Med 3 2003 107 112
65. M. Cattaneo, A. D'Angelo, and M.T. Canciani Effect of oral aspirin on plasma levels of vitamin K-dependent clotting factors-studies in healthy volunteers Thromb Haemost 59 1988 540
66. S. Husain, N.P. Andrews, D. Mulcahy, J.A. Panza, and A.A. Quyyumi Aspirin improves endotelial dysfunction in atherosclerosis Circulation 97 1998 716 720
67. R.K. Kharbanda, B. Walton, and M. Allen Prevention of inflammation-induced endothelial dysfunction. A novel vasculo-protective action of aspirin Circulation 105 2002 2600 2604
68. F. Catella-Lawson, M.P. Reilly, and S.C. Kapoor Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N Engl J Med 345 2001 1809 1817
69. A.D. Michelson, M. Cattaneo, and J.W. Eikelboom Aspirin resistance: position paper of the Working Group on Aspirin Resistance J Thromb Haemost 3 2005 1309 1311
70. C. Patrono Aspirin resistance: definition, mechanisms and clinical read-outs J Thromb Haemost 1 2003 1710 1713
71. G. De Gaetano, and C. Cerletti Aspirin resistance: a revival of platelet aggregation tests? J Thromb Haemost 1 2003 1710 1713
72. M.D. Carcao, V.S. Blanchette, and J.A. Dean The platelet function analyser (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children Br J Haematol 101 1998 70 73
73. S. Israels, T. Cheang, and E.M. McMillan-Ward Evaluation of primary hemostasis in neonates with a new in vitro platelet function analyser J Pediatr 138 2001 116 119
74. M.D. Reller Congenital heart disease: current indications for antithrombotic therapy in pediatric patients Curr Cardiol Rep 3 2001 90 95
75. S.M. Bradley, R.M. Sade, F.A. Crawford Jr., and M.R. Stroud Anticoagulation in children with mechanical valve prostheses Ann Thorac Surg 64 1997 30 34
76. Y. Tokunaga, S. Ohga, S. Suita, T. Matsushima, and T. Hara Moyamoya syndrome with spherocytosis: effect of splenectomy on strokes Pediatr Neurol 25 2001 75 77
77. M. Cattaneo Aspirin and clopidogrel. Efficacy, safety and the issue of drug resístanse Arterioscler Thromb Vasc Biol 24 2004 1980 1987
78. A. Zakarija, N. Bandarenko, and D.K. Pandey Clopidogrel-Associated TTP. An update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the food and drug administration Stroke 35 2004 533 537
79. A.T. Nurden, C. Poujol, C. Durrieu-Jais, and P. Nurden Platelet glycoprotein IIb/IIIa inhibitors. Basic and clinical aspects Arterioscler Thromb Vasc Biol 19 1999 2835 2840
80. R. Foster, and L. Wiseman Abciximab: an updated review of its use in ischaemic heart disease Drugs 56 1998 629 665
81. J.W. Newburger, M. Takahashi, and M.A. Gerber Diagnosis, treatment and long-term management of Kawasaki disease. A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Association Circulation 110 2004 2747 2771
82. R.V. Williams, V.M. Wilke, L.Y. Tani, and L.L. Minich Does abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 109 1 2002 URL: http//www.pediatrics.org/cgi/content/full/109/1/e4.
83. H.R. Buller, G. Agnelli, R.D. Hull, T.M. Hyers, M.H. Prins, and G.E. Raskok Antithrombotic therapy for venous thromboembolic disease. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 401S 428S
84. Paediatric Stroke Working Group. Stroke in childhood: clinical guidelines for diagnosis, management and rehabilitation, 2004. http://www.xcplondon.ac.uk/ pubs/books/childstroke/ (accessed June 1, 2005).
85. M.A. Crowther, J.S. Ginssberg, and J. Julian A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome N Engl J Med 349 2003 2577
86. G. Finazzi, R. Marchioli, and V. Brancaccio A randomized clinical trial of high intensity warfarin vs. conventional antithrombotic therapy for the preventioof recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) J Thromb Haemost 3 2005 828 853
87. M.D. Freed, J.F. Keane, and A. Rosenthal The use of heparinization to prevent arterial thrombosis after percutaneous cardiac catheterization in children Circulation 50 1974 565 569
88. M.D. Freed, A. Rosenthal, and D. Fyler Attempts to reduce arterial thrombosis after cardiac catheterization in children: use of percutaneous technique and aspirin Am Heart J 87 1974 283 286
89. P.S. Rao, M.K. Thapar, and J.H. Rogers Effect of intraarterial injection of heparin on the complications of percutaneous arterial catheterization in infants and children Catheter Cardiovasc Diagn 7 1981 235 246
90. A. Saxena, R. Gupta, R.K. Kumar, S.S. Kothari, and H.S. Wasir Predictors of arterial thrombosis after diagnostic cardiac catheterization in infants and children randomised to two heparin dosages Catheter Cardiovasc Diagn 41 1997 400 403
91. D.A. Girod, R.A. Hurwitz, and R.L. Caldwell Heparinization for the prevention of thrombosis following pediatric percutaneous arterial catheterization Pediatr Cardiol 3 1982 175 180
92. R.M. Grady, P.R. Eisenberg, and N.D. Bridges Rational approach to use of heparin during cardiac catheterization in children J Am Coll Cardiol 25 1995 725 729
93. Z.R. Bulbul, M.O. Galal, and E. Mahmoud Arterial complications following cardiac catheterization in children < 10 kg Asian Cardiovasc Thorac Ann 10 2002 129 132
94. B. Roschitz, A. Beitzke, and A. Gamillscheg Signs of thrombin generation in pediatric cardiac catheterization with unfractionated heparin bolus or subcutaneous low molecular weight heparin for antithrombotic cover Thromb Res 111 2003 335 341
95. F. Cetta, L.C. Graham, L.L. Wrona, M.J. Arruda, and J.M. Walenga Argatroban use during pediatric interventional cardiac catheterization Catheter Cardiovasc Interv 61 2004 147 149
96. T. Ino, L.N. Benson, and R.M. Freedom Thrombolytic therapy for femoral artery thrombosis after pediatric cardiac catheterization Am Heart J 115 1988 633 639
97. D.N. Salem, P.D. Stein, and A. Al-Ahmad Prosthetic valves in children and adolescents Am Heart J 121 1991 557 568
98. L.M. Bradley, F.M. Midgley, D.C. Watson, P.R. Getson, and L.P. Scott III Anticoagulation therapy in children with mechanical prosthetic cardiac valves Am J Cardiol 56 1985 533 535
99. A.M. Borkon, L. Soule, B.A. Reitz, V.L. Gott, and T.J. Gardner Five-year follow-up after valve replacement with the St. Jude Medical valve in infants and children Circulation 74 1986 110 115
100. A. El Makhlouf, B. Friedli, I. Oberhansli, J.C. Rouge, and B. Faidutti Prosthetic heart valve replacement in children J Thorac Cardiovasc Surg 93 1987 80 85
101. D.G. Human, H.S. Joffe, C.B. Fraser, and C.N. Barnard Mitral valve replacement in children J Thorac Cardiovasc Surg 83 1982 873 877
102. A. Milano, P.R. Vouhe, and F. Baillot-Vernant Late results after left-sided cardiac valve replacement in children J Thorac Cardiovasc Surg 92 1986 218 225
103. S. Stewart, D. Cianciotta, C. Alexson, and J. Manning The long-term risk of warfarin sodium therapy and the incidence of thromboembolism in children after prosthetic cardiac valves J Thorac Cardiovasc Surg 93 1987 551 554
104. M.S. Schaffer, D.R. Clarke, D.N. Campbell, C.K. Madigan, J.W. Wiggins Jr., and R.R. Wolfe The St. Jude Medical cardiac valve and children: role of anticoagulant therapy J Am Coll Cardiol 9 1987 235 239
105. M.J. Antunes, K.M. Vanderdonck, and M.J. Sussman Mechanical valve replacement in children and teenagers Eur J Cardiothorac Surg 3 1989 222 228
106. G. Champsaur, J. Robin, and F. Trone Mechanical valve in aortic position is a valid option in children and adolescents Eur J Cardiothorac Surg 11 1997 117 122
107. H.I. Bussey, D. Horstkotte, N. Miller, and S.G. Pauker Antithrombotic therapy in valvular heart disease-native ad prosthetic. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 457S 482S
108. F. Newall, C. Barnes, H. Savoia, J. Campbell, and P. Monagle Warfarin therarpy in children who require long-term total parenteral nutrition Pediatrics 12 2003 386 388
109. M. Jahangiri, D.B. Ross, A.N. Redington, C. Lincoln, and E.A. Shinebourne Thromboembolism after the Fontan procedure and its modifications Ann Thorac Surg 58 1994 1409 1414
110. D. Rosenthal, A. Friedman, S. Kleinman, G. Kopf, L. Rosenfeld, and W. Hellenbrand Thromboembolic complications after Fontan operations Circulation 92 1995 II 287 II 293 [Suppl]
111. D.A. Fyfe, C.H. Kline, R.M. Sade, and P.C. Gillette Transesophageal echocardiography detects thrombus formation not identified by transthoracic echocardiography after the Fontan operation J Am Coll Cardiol 18 1991 1733 1737
112. L.K. Shirai, D.N. Rosenthal, B.A. Reitz, R.C. Robbins, and A.M. Dubin Arrhythmias and thromboembolic complications after the extra cardiac Fontan operation J Thorac Cardiovasc Surg 115 1998 499 505
113. P. Monagle, A. Cochrane, B. McCrindle, L. Benson, W. Williams, and M. Andrew Thromboembolic complications after Fontan procedures-the role of prophylactic anticoagulation J Thorac Cardiovasc Surg 115 1998 493 498
114. P. Monagle, and T.R. Karl Thromboembolic problems after Fontan operation Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 555 2002 36 47
115. M.L. Jacobs The Fontan operation, thromboembolism and anticoagulation: a reappraisal of the sinle bullet theory J Thorac Cardiovasc Surg 129 2005 491 495
116. R. Kaulitz, G. Ziemer, and R. Rauch Prophylaxis of thromboembolic complications after the Fontan operation (total cavopulmonary anastomosis) J Thorac Cardiovasc Surg 129 2005 569 575
117. K.A. Al Jubair, M.R. Al Falig, and A.S. Al Jarallah Results of 546 Blalock-Taussig shunts performed in 478 patients Cardiol Young 8 1998 486 490
118. R.M. Berger, G. Bol-Raap, W.J. Hop, A.J. Bogers, and J. Hess Heparin as a risk factor for perigraft seroma complicating modified Blalock-Tassig shunt J Thorac Cardiovasc Surg 116 1998 286 292
119. J.C. Mullen, G. Lemermeyer, and M.J. Bentley Modified Blalock-Taussig shunts: to heparinize or not to heparinize? Can J Cardiol 12 1996 645 647
120. V. Sing, S. Pillai, and S. Kulkarni Thrombolysis with percutaneous balloon angioplasty of a blocked modified Blalock-Taussig shunt Indian Heart J 56 2004 673 676
121. M. Reis, H. Singer, and M. Hofbeck Thrombolysis of a modified Blalock-Taussig shunt with recombinant tissue plasminogen activator in a newborn infant with pulmonary atresia and ventricular septal defect Br Heart J 72 1994 201 202
122. M. Peuster, C. Fink, H. Bertram, T. Paul, and G. Hausdorf Transcatheter recanalization and subsequent stent implantation for the treatment of early postoperative thrombosis of modified Blalock-Tassig shunts in two children Catheter Cardiovasc Diagn 45 1998 405 408
123. N. Sreeram, K. Walsh, and I. Peart Recanalisation of an occluded modified Blalock-Tassig shunt by balloon dilatation Br Heart J 70 1993 474 475
124. S.A. Qureshi, and S. Sivasankaran Role of stents in congenital heart disease Expert Rev Cardiovasc Ther 3 2005 261 269
125. M. Okubo, and L.N. Benson Intravascular and intracardiac stents used in congenital heart disease Curr Opin Cardiol 16 2001 84 91
126. K.M. Shaffer, C.E. Mullins, and R.G. Grifka Intravascular stents in congenital heart disease: short and long term results from a large single centre experience J Am Coll Cardiol 31 1998 661 667
127. J.G. Coles, I. Yemets, and H.K. Najm Experience of repair of congenital heart defects using adjunctive endovascular devices J Thorac Cardiovasc Surg 110 1995 1513 1519